The biotechnology sector witnessed a striking demonstration of expedited drug development this week, with Boehringer Ingelheim receiving FDA approval for an innovative lung cancer therapy
As reported by Pharma Times, Elevara Medicines has initiated a phase 2b clinical study evaluating ELV001, an investigational oral CDK4/6 inhibitor, in people with rheumatoid
Pictured above: Giuliana Noratto, Ph.D., (left) and Lauren Stranahan, Ph.D., led research showing that compounds in dark sweet cherries may help slow the growth and
Daiichi Sankyo has taken a significant step toward expanding treatment options in Japan by submitting regulatory approval for Enhertu, an advanced cancer-fighting drug designed to
As reported by FiercePharma, the U.S. Food and Drug Administration has approved the first fully independent generic version of GlaxoSmithKline’s widely used asthma inhaler, Flovent,
You can not see, hear, or touch my rare condition. I STINK! (LITERALLY) I wasn’t sure if I was going to tell my story. But
Researchers have created a fundamentally new class of HIV-fighting molecules by combining two separate antiviral mechanisms into a single engineered protein. Early laboratory results, reported
As reported on BioPharmaDive, UCB has reported positive results from a head-to-head clinical trial showing that its anti-inflammatory biologic Bimzelx was more effective than AbbVie’s
Editor’s Note: Patient Worthy is proud and honored to share Jennifer’s story with cystic fibrosis and colon cancer, originally published on the Cystic Fibrosis Research
The biotechnology sector experienced significant positive developments this week, with Xenon Pharmaceuticals’ seizure medication achieving a decisive late-stage victory while regulatory pathways accelerated for several
As reported on Healio, glucagon-like peptide-1 (GLP-1) receptor agonists, best known for treating diabetes and obesity, are emerging as unexpected players in breast cancer care.
CAR T- cells are immune cells that are engineered in a laboratory to attack cancer. The therapy has worked as planned for certain blood cancers
Artios Pharma has achieved a significant milestone in cancer treatment development with the U.S. Food and Drug Administration’s granting of Fast Track designation to ART6043,
As reported on drugs.com, Bristol Myers Squibb (BMS) has announced encouraging interim results from the Phase 3 portion of the SUCCESSOR-2 clinical trial evaluating oral
As reported on FierceBioTech, the U.S. Food and Drug Administration has released its complete response letter (CRL) detailing why it declined to approve Regenxbio’s experimental
As covered on PharmaBiz, Roche has reported topline results from the phase III persevERA Breast Cancer study, which evaluated the oral selective oestrogen receptor degrader
Editor’s Note: Patient Worthy is proud to share this article from our friends at the Courageous Parents Network. A parent often can sense when there
Daiichi Sankyo has taken a significant step forward in expanding treatment options for early-stage breast cancer patients by submitting a supplemental New Drug Application (sNDA)
If you or someone you love is navigating this diagnosis, understanding the “why” behind treatment can make the journey feel a little more manageable. 🩷
It can also help you ask better questions, feel more confident in your care plan, and stay empowered every step of the way. Knowledge doesn't take away the challenges- but it can give you clarity, direction, and a sense of control in a time that may feel overwhelming. Click on the link below to share your story- bit.ly/3VuxFDV
#BreastCancerAwareness #WomensHealth #PatientWorthy
March is Women’s History Month-a time to recognize and uplift the women who inspire progress in our communities, workplaces, and lives, especially those shaping the history of the medical field. Today and every day we celebrate women’s courage, leadership, and lasting influence in healthcare and beyond.
#WomensHistoryMonth #CelebrateWomen #WomenInMedicine #VoicesThatMatter
Today we recognize World Down Syndrome Day. 💛💙
A day to celebrate the beauty, strength, and individuality of people with Down syndrome- while also raising awareness about inclusion, respect, and equal opportunities for all.
Down syndrome is simply a genetic difference- an extra copy of chromosome 21- that makes each person uniquely themselves. It doesn't define limits, potential, or worth.
Let today be a reminder to move beyond awareness into action- by creating spaces where everyone is valued, included, and supported to thrive.
Different, not less.
#worlddownsyndromeday #nothingdownaboutit #PatientWorthy
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
